Patel Sanjay, Berry Leslie R, Chan Anthony K C
Henderson Research Centre, 711 Concession Street, Hamilton, Canada L8V 1C3.
J Biochem. 2007 Jan;141(1):25-35. doi: 10.1093/jb/mvm001. Epub 2006 Dec 13.
Antithrombin (AT) inhibition of coagulation enzymes is catalyzed by unfractionated heparin (UFH) and other heparinoids. Reaction proceeds either via conformational activation of the inhibitor or template-mediated binding of both inhibitor and protease. We investigated if the relative inhibition rates of AT + UFH and covalent AT-heparin conjugate (ATH) with coagulation factors might be indicative of the mechanism involved. Rates were determined by discontinuous assay and mechanisms were probed by a variety of binding studies with UFH or ATH heparin chains. Rates were increased more than 2-fold with ATH over AT + UFH in reactions with thrombin, factor (F) VIIa + tissue factor + Ca2+ + lipid, FIXa and FXIa, but not with FXa or FXIIa. In comparison, UFH or ATH heparin binding (evidence of a template mechanism) was only observed with thrombin, tissue factor, FIXa and FXIa. Thus, inhibition rate enhancement by conjugation of AT with heparin were predictive of inhibitor.enzyme template bridging by heparin. Rationales behind this novel concept are discussed.
抗凝血酶(AT)对凝血酶的抑制作用由普通肝素(UFH)和其他类肝素催化。反应通过抑制剂的构象活化或抑制剂与蛋白酶的模板介导结合进行。我们研究了AT + UFH和共价AT-肝素共轭物(ATH)对凝血因子的相对抑制率是否可能表明所涉及的机制。通过间断测定法确定抑制率,并通过对UFH或ATH肝素链进行各种结合研究来探究机制。在与凝血酶、因子(F)VIIa + 组织因子 + Ca2+ + 脂质、FIXa和FXIa的反应中,ATH的抑制率比AT + UFH增加了2倍以上,但与FXa或FXIIa反应时则不然。相比之下,仅在凝血酶、组织因子、FIXa和FXIa中观察到UFH或ATH肝素结合(模板机制的证据)。因此,AT与肝素结合导致的抑制率提高预示着肝素介导的抑制剂-酶模板桥接。讨论了这一新概念背后的基本原理。